[1] SHOUGHY S S. Topical tacrolimus in anterior segment inflammatory disorders[J]. Eye Vis (Lond),2017,4:7. doi:  10.1186/s40662-017-0072-z
[2] LIN H R, SUNG K C. Carbopol/pluronic phase change solutions for ophthalmic drug delivery[J]. J Control Release,2000,69(3):379-388. doi:  10.1016/S0168-3659(00)00329-1
[3] PASTOR-CLERIGUES A, SERRANO A, MILARA J, et al. Evaluation of the ocular tolerance of three tacrolimus topical pharmaceutical preparations by bovine corneal opacity and permeability test[J]. Curr Eye Res,2016,41(7):890-896. doi:  10.3109/02713683.2015.1082187
[4] ABEYSIRI P, JOHNSTON N R, MOLTENO A C. The use of topical tacrolimus 0.1% skin ointment for anterior segment conditions: a case series[J]. Ophthalmol Eye Dis,2010,2:5-8.
[5] TAM P M, YOUNG A L, CHENG L L, et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD[J]. Bone Marrow Transplant,2010,45(5):957-958.
[6] KUTLEHRIA S, VHORA I, BAGDE A, et al. Tacrolimus loaded PEG-cholecalciferol based micelles for treatment of ocular inflammation[J]. Pharm Res,2018,35(6):117. doi:  10.1007/s11095-018-2376-7
[7] SILVA-CUNHA A, DA SILVA G R, DE CASTRO W V, et al. Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus[J]. J Ocul Pharmacol Ther,2014,30(1):59-65. doi:  10.1089/jop.2013.0128
[8] OHASHI Y, EBIHARA N, FUJISHIMA H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis[J]. J Ocul Pharmacol Ther,2010,26(2):165-174. doi:  10.1089/jop.2009.0087
[9] HÄGERSTRÖM H, PAULSSON M, EDSMAN K. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method[J]. Eur J Pharm Sci,2000,9(3):301-309. doi:  10.1016/S0928-0987(99)00070-6
[10] LIU Y, LU W L, WANG J C, et al. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization[J]. J Control Release,2007,117(3):387-395. doi:  10.1016/j.jconrel.2006.11.024
[11] LEDERER C M Jr, HAROLD R E. Drop size of commercial Glaucoma medications[J]. Am J Ophthalmol,1986,101(6):691-694. doi:  10.1016/0002-9394(86)90771-3
[12] 魏刚. 体温敏感眼用凝胶的研究[D]. 沈阳: 沈阳药科大学, 2002.